Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 4,497 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 4,497 shares of the firm’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the sale, the director now owns 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jeffrey William Henderson also recently made the following trade(s):

• On Tuesday, April 1st, Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15.
• On Monday, March 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00.
• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $60.57 on Tuesday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market cap of $7.48 billion, a price-to-earnings ratio of 17.66, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a 50 day moving average price of $60.56 and a 200-day moving average price of $55.20. Halozyme Therapeutics, Inc. has a 1-year low of $37.97 and a 1-year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HALO. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Friday. JPMorgan Chase & Co. raised their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research report on Monday, April 21st. Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $62.89.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $69,000. Retirement Systems of Alabama raised its position in shares of Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares during the last quarter. Shaker Investments LLC OH raised its position in shares of Halozyme Therapeutics by 12.3% during the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock worth $3,601,000 after purchasing an additional 8,249 shares during the last quarter. Foster & Motley Inc. raised its position in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after purchasing an additional 12,630 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $731,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.